A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 21 Apr 2018
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE AD-1
- Sponsors Eli Lilly; Eli Lilly Japan
- 26 Mar 2018 Planned End Date changed from 1 Jan 2021 to 1 Jan 2019.
- 26 Mar 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2018.
- 09 Mar 2018 Planned End Date changed from 15 Feb 2019 to 1 Jan 2021.